BridgeBio is demonstrably advanced its progress of an new therapy for amyloid heart disease, utilizing the investigational drug. Initial trial information indicates significant improvements for patients diagnosed with https://biotech018731.blogsumer.com/40973426/firm-progresses-amyloidosis-therapy-with-attruby